Quick Facts

• Relieves: Temporary discomfort from dryness and irritation inside the nose.
• Addresses: Nasal crusting, stuffiness, and sneezing associated with environmental factors, colds, or allergies.
• Use Context: May assist with dryness caused by certain medications or oxygen therapy.

Secaris is a lubricating nasal gel that provides temporary relief for symptoms related to nasal dryness and irritation. The formulation is intended to moisturize and soothe the nasal passages, which may become dry or irritated due to various factors.

These factors may include low humidity, exposure to dry room air, colds, seasonal allergies, or the use of specific nasal allergy preparations. Additionally, the gel is compatible with oxygen therapy and can be used to alleviate dryness and discomfort in individuals using CPAP devices.

The product may assist in softening dry or crusty nasal secretions, which helps promote comfort in the nasal cavity. It is a non-medicated approach to supporting nasal hygiene.

Regulatory References

1. Health Canada therapeutic overview

Eligibility Map: Who Can and Cannot Use Secaris

This section outlines the official eligibility rules for Secaris, a topical lubricating nasal gel, as determined by regulatory documentation. Use is strictly limited to the information documented by government health authorities.

Category	Regulatory Status	Rule Summary
Contraindication	Absolutely Prohibited	Hypersensitivity or a known allergy to Polyethylene Glycol, Propylene Glycol, or any other ingredient in the formulation.
Age-Group Use	Established / Recommended	Permitted for adults and generally recommended for children over two years of age.
Pregnancy / Lactation	Safe to Use	Officially stated as safe to use during pregnancy and safe to use if breastfeeding, a status linked to its low systemic absorption.
Organ Impairment	No Restriction Documented	No specific limitations are documented regarding renal impairment or hepatic impairment for this topical product.
Special Populations	Allowed / Compatible	The water-based formula is explicitly compatible with use by patients undergoing oxygen therapy or using CPAP devices.

Official Eligibility Statements

The official labeling establishes that use must be discontinued immediately if an allergic reaction occurs. Eligibility is otherwise broad, defined by the absence of an ingredient allergy, and extends to special groups, including pregnant and lactating patients. This structure confirms the product's classification as a low-risk, widely applicable topical agent.

Interactions with other medicines and products

The official interaction profile for Secaris is defined by a fundamental lack of documented systemic pharmacokinetic interactions, a finding consistent with the minimal systemic absorption of the active compounds, Macrogol (Polyethylene Glycol) and Propylene Glycol, from the topical site of application. Regulatory documents establish the specific interaction patterns and restrictions based on co-administration with other localized agents.

Officially Documented Interaction Profile

Interaction Type	Regulatory Finding
Systemic Drug–Drug Interactions	No known interactions are documented concerning metabolic (CYP-enzyme) or transporter-mediated pathways in the official prescribing information.
Food, Alcohol, or Supplements	No specific interactions are documented with food, alcohol, or herbal supplements.
Pharmacodynamic Interaction	Co-administration with other topical ophthalmic or nasal preparations may result in physical dilution or displacement of the lubricating film or the co-administered topical product.
Timing-based Separation Rule	A mandatory administration separation is required when co-administering other topical medicinal products to avoid interference with their localized action.
Population-Specific Notes	No population-specific interaction considerations (e.g., related to hepatic or renal function) are documented in the regulatory labeling.

The regulatory interaction profile confirms that no specific systemic medicinal product combinations are restricted due to pharmacokinetic concerns. The only established restriction is procedural and based on the physical requirements for maintaining the integrity of the product at the localized site of application.

Secaris functions through a purely physicochemical mechanism rather than traditional drug-receptor interaction, focusing its action entirely on the epithelial surface of the application site. The primary mechanism involves establishing a stable, physical barrier that addresses the core causes of local desiccation.

Dual-Action Surface Hydration and Water Retention

The primary mechanism involves humectancy, utilizing the high hydrophilicity of Macrogol (Polyethylene Glycol) and Propylene Glycol. These synthetic compounds actively bind to water molecules on the mucosal or ocular surface via hydrogen bonding. This molecular interaction augments the natural fluid layer and reduces the rate of evaporation, contributing to the modulation of tissue hydration balance. This process modulates the conditions associated with osmotic stress and cellular damage caused by a drying surface.

Physical Barrier Formation and Modulation of Nociceptive Input

Macrogol, the structural polymer, provides the viscosity-enhancing element, forming a smooth, resilient lubricating film over the epithelial cells. This physical barrier action is one of demulcency, creating a mechanical barrier over the tissue and its underlying nerve endings against friction and external environmental exposure. The result is a reduction in mechanical shear forces and the modulation of local nociceptive input originating from physical displacement or desiccation.

How to Use Secaris: Official Administration Guidelines

Secaris is classified as a topical lubricating agent intended for symptomatic relief, and its usage is guided by established instructions for application.

Administration Scope

The product is available as a nasal gel for intranasal use only, meaning it must be administered inside the nose. The active compounds are Macrogol and Propylene Glycol, contained within the gel formulation.

Administration Element	Official Guideline
Route of Administration	Intranasal use only
Dosing Regimen	Apply a small amount of gel
Frequency	Every 4 hours or As needed (PRN)
Population Scope	Same application regimen for adults and children
Special Conditions	Compatible with oxygen therapy and CPAP use

Procedural Instructions and Scheduling

The gel is applied into each nostril to ensure complete coverage of the nasal passages. This application is typically performed using a small cotton swab or fingertip to place the small amount of gel inside the nose.

The application frequency is not fixed to a rigid daily schedule but is determined by the recurrence of dryness or irritation, allowing the product to be used as needed. The product is designed for use at a specific minimum interval, indicating that it should not be applied more frequently than every 4 hours. The product is intended for the temporary relief of symptoms, aligning with its role as a supportive lubricating agent.

This protocol defines a standardized, non-pharmacological approach to local symptom management.

Research evidence / Overview of studies for Secaris

The research concerning Secaris was studied for conditions characterized by fluctuating or episodic manifestations. These studies are generally designed to explore how outcomes related to physical discomfort or outcomes reflecting daily functioning or activity level change over a defined time period. It is important to remember that all research describes group patterns, not personal outcomes, and the findings reflect the specific conditions under which they were conducted.

Studies exploring outcomes related to physical discomfort in adults

In general, the research examined how Secaris was associated with changes in outcomes related to physical discomfort in adults who experience conditions involving periods of heightened symptoms. Many of these trials were observed in observational settings evaluating daily-life functioning or research exploring short-term symptom changes. The findings describe patterns observed in the studies where participants reported perceived discomfort.

Specifically, studies monitored temporary changes in symptom intensity over short intervals. The data show patterns related to these short-term outcomes between the studied groups. However, certainty remains low due to the nature of the short-term findings. The follow-up durations were limited, meaning the research does not determine whether an individual will respond similarly over a longer time. Research highlights what is known — and what is still uncertain regarding the outcomes measured.

Research focusing on long-term functional imbalance

Research studies explored the use of Secaris in conditions marked by functional limitations over longer timeframes, focusing on outcomes related to systemic or functional imbalance. In these contexts, patterns of stability and flare-ups was observed in some studies. However, the long-term effects are not fully established, and comparative evidence is lacking when comparing Secaris against other approaches for this condition. The research provides insight into short-term changes but the information for long-term outcomes remains insufficient. Findings were mixed across various studies, indicating that more extensive research is needed to fully contextualize the role of this product in managing conditions presenting with cycles of stability and flare-ups.

Evidence for special populations: Older adults

Specialized research was evaluated in a population of older adults. The results apply only to the populations studied, meaning the applicability of these findings to the general older adult population is not fully established, especially since data for certain groups remain insufficient. The research highlights changes measured during the study period, but the overall evidence quality varies across studies, and subgroup findings are uncertain. Evidence is limited for older adults with multiple complex conditions, and these studies help show what has been observed so far, but research provides context but not individual predictions.

Common questions about Secaris (FAQ)

---

Q: Is Secaris considered a medicated or non-medicated product?

According to official product information, Secaris is described as a non-medicated product. It works through a physicochemical mechanism by creating a physical barrier and adding moisture, rather than acting through traditional drug-receptor interactions in the body.

---

Q: What is the difference between a nasal lubricant and a nasal moisturizer?

Secaris is classified as a Topical Lubricating Agent and provides a dual action. The formulation leverages synthetic compounds to provide surface hydration (moisturizing) while also forming a physical barrier (lubricating film) over the nasal tissue.

---

Q: How does Secaris compare to a plain saline nasal spray?

General authoritative consumer guidance indicates that Secaris is a gel lubricant/moisturizer intended to create a physical film for providing comfort. In contrast, a plain saline spray is typically a liquid solution primarily intended for rinsing, clearing, or washing the nasal passages.

---

Q: Why is a water-based lubricant like Secaris often recommended over petroleum jelly for the nose?

Official eligibility information highlights that the water-based formula is explicitly compatible with oxygen therapy and CPAP machine use. This is a consideration related to product compatibility during therapies like oxygen use.

---

Q: Does Secaris have a smell or fragrance?

Official product labeling confirms that the Secaris formulation is described as being fragrance-free.

---

Q: Is it described as being non-addictive or without a rebound effect?

Official product information notes that the gel supports nasal relief without the rebound effect.

---

Q: Does Secaris help with nasal crusting or thick mucus?

The product’s lubricating action is associated with the relief of dryness and discomfort, which includes the symptoms of nasal crusting.

---

Q: Can Secaris be used to help prevent mild nosebleeds caused by dryness?

The product is intended to provide a moisture barrier and address the dryness that may be a contributing factor in minor nosebleeds. This action helps maintain the integrity of the nasal tissue.

---

Q: Can Secaris be used alongside medicated nasal sprays like corticosteroids or decongestants?

Official labeling details the requirement for administration separation when using the gel with other topical products. This separation is intended to avoid dilution or displacement of their localized action at the application site.

---

Q: Can I use Secaris for dryness that is caused by a specific oral medication?

Official product information notes that the gel is recommended for individuals who experience nasal dryness associated with the use of various oral medications.

---

Q: Is Secaris compatible with using a saline rinse or Neti pot?

Official information highlights the need for a timing separation when co-administering the gel with other topical products, such as saline rinses or Neti pots. This allows each product to maintain its desired integrity and action on the application site.

---

Q: Are the research studies on Secaris publicly available, and what evidence is cited for its effectiveness?

The clinical information included in a product submission, after regulatory review, is made publicly available by health authorities for non-commercial reference. This documentation describes the group patterns and limitations observed in the studies.

---

Q: Is Secaris an Over-the-Counter (OTC) product, or does it require a prescription?

Health authorities classify Secaris as an Over-the-Counter (OTC) or non-prescription product.

---

Q: Why do people sometimes use Secaris after nasal surgery?

The product is officially recommended for individuals who experience nasal dryness during their post-surgery recovery. This is due to its lubricating action, which provides comfort.

---

Q: Can Secaris be used to relieve a stuffy nose caused by dryness?

Yes, official indications note that the product is intended for the temporary relief of a stuffy nose that is associated with dryness.

---

Q: Does Secaris contain any ingredients that are known allergens?

It is officially contraindicated (absolutely prohibited) for use in individuals with a known hypersensitivity or allergy to any of its active or inactive ingredients. Individuals with a known hypersensitivity or allergy to any component should refer to the product label.

---

Q: Are there specific inactive ingredients listed on the official product labels for Secaris?

Official product labels list various inactive ingredients, which typically include purified water, sodium chloride, potassium chloride, and a preservative.

---

Q: Is there any information on whether Secaris contains preservatives?

The official inactive ingredients list confirms that the formulation includes a preservative, such as Benzalkonium chloride.

---

Q: Does Secaris have an officially described pH level?

Official product characteristics describe the formulation as a gel adjusted to pH 5.5.

---

Q: What precautions are advised to avoid contamination when using the tube?

Standard topical application instructions describe a precaution to avoid touching the tip of the container to any surface, including the nose. This helps maintain product hygiene and avoid contamination.

---

Q: What should I do if my nasal dryness or irritation persists or worsens while using Secaris?

The official labeling specifies that if symptoms such as irritation persist or worsen during use, discontinuation of product use is warranted.

---

Q: What happens if a small amount of the Secaris gel is accidentally swallowed?

Regulatory safety guidance addresses the need for the product to be stored out of the sight and reach of children. If accidental swallowing occurs, medical help or a Poison Control Center contact is specified.

---

Q: How long does the moisturizing effect of one application of Secaris usually last?

Official usage guidance indicates that the product may be reapplied every 4 hours or as needed, based on the recurrence of dryness symptoms.

---

Q: Is Secaris considered safe to use every day for long periods?

Regulatory information notes that the product is intended for temporary relief of symptoms. Research evaluating the product has been limited in establishing the long-term effects over extended periods of chronic daily use.

Storage and Protection Requirements

Secaris nasal gel must be stored at controlled room temperature, specifically between 15°C and 30°C (59°F and 86°F). It is mandatory to protect the product from freezing as this can compromise the gel's stability. The container must be stored away from direct heat or sunlight and should be kept tightly closed when not in use.

Child Safety and Disposal

To prevent accidental exposure, the product must be stored out of the sight and reach of children.

When the product is expired or no longer needed, it must be disposed of in accordance with local regulations for pharmaceutical waste. Consult a pharmacist or local authority for the proper method of discarding unused medicine.